NEW YORK, June 30 — A securities fraud class action lawsuit has been filed against GRAIL, Inc. and certain senior executives, alleging the company misled investors about its NHS-Galleri cancer trial results in violation of federal securities laws. The law firm Bleichmar Fonti & Auld LLP announced the action on Tuesday. The suit follows a 50% collapse in GRAIL’s stock price — a drop the firm attributes to the company’s alleged misrepresentations about the trial.
GRAIL, which trades on the Nasdaq under the ticker GRAL, has been developing a blood test for early cancer detection. The NHS-Galleri trial is the company’s flagship clinical study, designed to validate the test’s performance in a large screening population.
Under the hood, the technical reality of such trials is that their results determine not just regulatory approval but investor confidence in the entire commercial proposition. The complaint contends that GRAIL’s public statements about the trial’s outcomes were materially false and misleading. When the truth emerged — the detail that matters — the stock lost half its value in a single move, wiping out substantial shareholder value.
Bleichmar Fonti & Auld is a leading securities law firm. It is representing investors who purchased GRAIL securities during the relevant period.
The case alleges that the company and its executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as SEC Rule 10b-5, which prohibits fraud in connection with the purchase or sale of securities. As ever, the precise nature of the alleged misrepresentations will be central to the litigation. The lawsuit is at an early stage, and no court has yet ruled on the merits of the claims.
Investors who bought GRAIL shares during the class period should watch for deadlines to seek appointment as lead plaintiff. The case adds to a growing list of securities fraud actions targeting biotech firms whose trial disclosures fail to match market expectations.
